Nurse practitioner-led cardiometabolic program

1 paper5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Human trial1

Associations

Heart failure hospitalization

downin humans1

1 study

Nurse practitioner-led cardiometabolic program is associated with heart failure hospitalization in humans (18.2% to 4.7%).
“Heart failure hospitalization fell from 18.2% to 4.7% (P = .002).”
Human trialobesity-related HFpEF; single-center pre-post study12 months versus 12-month preenrollment period
Nurse Practitioner-Led Integration of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Prospective Clinical Effectiveness Study
The Journal of cardiovascular nursing13 Oct 2026

6-minute walk distance

upin humans1

1 study

Nurse practitioner-led cardiometabolic program is associated with 6-minute walk distance in humans (+48.3 ± 36.2 m).
“6-minute walk distance rose 48.3 ± 36.2 m (all P < .001).”
Human trialobesity-related HFpEF; single-center pre-post study12 months
Nurse Practitioner-Led Integration of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Prospective Clinical Effectiveness Study
The Journal of cardiovascular nursing13 Oct 2026

Kansas City Cardiomyopathy Questionnaire clinical summary score

upin humans1

1 study

Nurse practitioner-led cardiometabolic program is associated with Kansas City Cardiomyopathy Questionnaire clinical summary score in humans (+16.6 ± 11.3 points).
“Kansas City Cardiomyopathy Questionnaire Clinical Summary Score improved 16.6 ± 11.3 points”
Human trialobesity-related HFpEF; single-center pre-post study12 months
Nurse Practitioner-Led Integration of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Prospective Clinical Effectiveness Study
The Journal of cardiovascular nursing13 Oct 2026

More on Kansas City Cardiomyopathy Questionnaire clinical summary score

Body weight

downin humans1

1 study

Nurse practitioner-led cardiometabolic program is associated with body weight in humans (decreased 6.2 ± 3.8 kg).
“Mean weight decreased 6.2 ± 3.8 kg”
Human trialobesity-related HFpEF; single-center pre-post study12 months
Nurse Practitioner-Led Integration of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Prospective Clinical Effectiveness Study
The Journal of cardiovascular nursing13 Oct 2026

GLP-1 RA use

upin humans1

1 study

Nurse practitioner-led cardiometabolic program is associated with GLP-1 RA use in humans (7.8% to 92.2%; 87.5% at target dose).
“GLP-1 RA use rose from 7.8% to 92.2% (87.5% at target dose).”
Human trialobesity-related HFpEF; single-center pre-post study12 months
Nurse Practitioner-Led Integration of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Prospective Clinical Effectiveness Study
The Journal of cardiovascular nursing13 Oct 2026

Latest

1 in 12 months

The Journal of Cardiovascular Nursing4 h

Nurse Practitioner-Led Integration of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: A Prospective Clinical Effectiveness Study

Non-randomised trial in 156 peopleGLP-1 receptor agonists

Paper